22 and in Peru 24% (15%–24%).
26 Also of note is when compared to the national target of HIV prevention and control, this figure is higher than that required to reach the 90-90-90 treatment targets. This is probably best explained by patients’ time on ARV therapy, lower baseline BMI measurement and CD4 count, poor adherence to medication, and low immunological failure, which increased the odds of unsuppressed viral load.
Unsuppressed viral load was 91% loweramong those on ARV therapy >2 years than those on ARVs >years. This finding is comparable to the Haiti study, where those that had been on ARV therapy for 2–3 years were all significantly less likely to achieve viral suppression.